Rosetta Genomics Ltd. announced revenue results for the first quarter of 2017. For the quarter, preliminary reveal revenue was approximately $600,000, representing growth of more than 50% compared with revenue of $389,000 for the fourth quarter of 2016 and more than double revenue of $282,000 reported for the third quarter of 2016.

The company affirms 2017 revenue and unit guidance for RosettaGX Reveal. For 2017, the company expects reveal revenue to be between $4.0 million and $5.0 million, and expects to process between 2,500 and 3,500 reveal units during the year.